VanVeggel FCJM, Chiosis G, Cameron RB, Reinhoudt DN. Preorganized Metallomacrocycles - Selective Receptor for Ammonia. Supramolecular Chem. 1994; 3:177-183.

Kremer FJB, Chiosis G, Engbersen JFJ, Reinhoudt DN. Improved Guannidinium Ion-Selectivity by Novel Calix[4]arene and Calix[6]arene Receptor Molecules on CHEMFETs. J. Chem. Soc. Perkin Trans2. 1994; 4: 677-681.

Vanaxelcastelli V, Cacciapaglia R, Chiosis G, VanVeggel FCJM, Mandolini L, Reinhoudt DN. The Uranyl Unit as Electrophilic Catalyst of Acyl Transfer Reactions. Inorg. Chem. Acta 1996; 246:181-193.

Chiosis G. Study Into the Cyclization of an Epoxy-Alcohol to the Energetically Disfavored Product by Peptides from Non-biased Combinatorial Libraries. Tetrahedron Lett. 2000; 41:801-806.

Zheng FF, Kuduk SD, Chiosis G, Munster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Identification of a Geldanamycin Dimer That Induces the Selective Degradation of HER-family Tyrosine Kinases. Cancer Res. 2000; 60:2090-2095.

Chiosis G, Rosen N, Sepp-Lorenzino L. LY294002-Geldanamycin Heterodimers as Selective Inhibitors of the PI3K and PI3K-related Family. Bioorg. Med. Chem. Lett. 2001; 11: 909-915.

Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells. Chem. Biol. 2001; 8:289-299.

Chiosis G, Boneca IG. Selective Cleavage of D-Ala-D-Lac by Small Molecules: Re-Sensitizing Resistant Bacteria to Vancomycin. Science 2001; 293: 1484-1487. Recommended Faculty of 1000 Biology

Lucas B, Rosen N, Chiosis G. Facile synthesis of 9-Alkyl-8-benzyl-9H-purin-6-ylamine Derivatives. J. Comb. Chem. 2001; 3: 518-520.

Chiosis G, Shtil A, Lucas B, Huezo H, Rosen N. Development of 9-alkyl-8-benzyl-9H-purin-6-ylamines as inhibitors of the hsp90 family. Clinic. Cancer Res. 2001, 7: 474 Suppl. S.

Boneca IG, Chiosis G. A new strategy for fighting vancomycin resistant-enterococci. APUA Newsletter 2002; 20: 1-3.

Chiosis G, Huezo H, Lucas B, Rosen N. Development of a Purine-based Novel Class of Hsp90 Binders That Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002; 10: 3555-3564.

Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG - Low target binding affinity and potent whole cell potency: finding an explanation. Eur. J. Cancer 2002; 38: 203B.

Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers C. BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100(8): 3041-3044.

Basso DB, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with hsp90 and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 2002; 277(42): 39858-39866.

Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG - Low target binding affinity and potent cell activity: Finding an explanation. Molec. Cancer Ther. 2003; 2: 123-129.

Yamamoto K, Garbaccio RM, Stachel SJ, Solit DB, Chiosis G, Rosen N, Danishefsky SJ. Target Oriented Total Synthesis as a Resource in the Discovery of Potentially Valuable Agents in Oncology: Cycloproparadicicol. Angew. Chemie 2003, 42: 1280-1284.

Boneca IG, Chiosis G. Vancomycin resistance: Occurrence, mechanism and therapeutic approaches. Expert Opinion on Therapeutic Targets, 2003; 7(3), 311-328.

Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets 2003, 3, 363-368.

Huezo H, Vilenchik M, Rosen N, Chiosis G. Microtiter cell-based assay for the detection of agents that alter cellular levels of Her2 and EGFR. Chem Biol. 2003, 10(7), 629-634.

Llauger L, Felts S, Huezo H, Rosen N, Chiosis G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg. Med. Chem. Lett. 2003, 13, 3975-3978.

He H, Llauger L, Rosen N, Chiosis G. General Method for the Synthesis of 8-Arylsulfanyl Adenine Derivatives, J. Org. Chem. 2004, 69, 3230-3232.

Vilenchik M, Solit D, Basso M, Huezo H, Lucas B, Huazhong H, Rosen N, Spampinato C, Modrich P, Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11, 787-797.

Kim J, Felts S, He H, Llauger L, Huezo H, Rosen N, Chiosis G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomolecular Screening 2004, 9(5):375-81.

Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90 – the vulnerable chaperone. Drug Discovery Today, 2004, 9(20):881-8.

Llauger L, He H, Chiosis G. Synthesis of 8-arylsulfoxyl/sulfonyl adenines. Tet. Lett. 2004, 45, 9549-9552.

Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G. 8-Arylsulfanyl and 8-Arylsulfoxyl Adenine Derivatives as Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2005, 48, 2892-2905.

Chiosis G, Brodsky J. The journey of small molecule microarrays: From proteins to mammalian cells - are we there yet? Trends Biotech. 2005, (6):271-4.

Chiosis G., Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Current medicinal chemistry-Anti-cancer agents. 2006, 6, 1-8.

He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G. Identification of Potent Water-Soluble Purine-Scaffold Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 2006, 49(1):381-90. Featured as “Hot Paper” and “Number 1 most cited” on the American Chemical Society site.

Chiosis G. Targeting chaperones in transformed systems – a focus on Hsp90 and cancer. Expert Opinion on Therapeutic Targets. 2006, 10(1):37-50.

De Martino G, Edler MC, La Regina G, Coluccia A, Barbera MC, Barrow D, Nicholson RI, Chiosis G, Brancale A, Hamel E, Artico M, Silvestri R. New Arylthioindoles: Potent Inhibitors of Tubulin Polymerization. 2. Structure-Activity Relationships and Molecular Modeling Studies. J Med Chem. 2006, 49(3):947-954.

Chiosis G, Aguirre J, Nicchitta CV. Synthesis of Hsp90 dimerization modulators. Bioorg. Med. Chem. Lett. 2006,16:3529–3532.

Chu F, Maynard JC, Chiosis G, Nicchitta CV, Burlingame AL. Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94. Protein Science 2006, (6):1260-9.

Chiosis G. Molecular chaperones as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 2006, 6(11):1161.

Chiosis G. Discovery and Development of Purine-Scaffold Hsp90 Inhibitors. Curr. Top. Med. Chem. 2006, 6(11):1183-1191.

Brodsky JF, Chiosis G. Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators. Curr. Top. Med. Chem. 2006, 6(11):1215-1225.

Chiosis G, Caldas Lopes E, Solit D. Hsp90 inhibitors – a chronicle from geldanamycin to today’s agents. Current Opinion in Investigational Drugs 2006 (6):534-41.

Chiosis G, Neckers L. Tumor Selectivity of Hsp90 Inhibitors – The Explanation Remains Elusive. ACS Chemical Biology 2006, (1):279-284.

Moulick K, Clement CC, Aguirre J, Kim J, Kang Y, Felts S, Chiosis G. Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorg. Med. Chem. Lett. 2006, (16):4515–4518.

Immormino RM, Kang Y, Chiosis G, Gewirth DT. Structural and Quantum Chemical Studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. J Med Chem. 2006 49(16):4953-4960.

Chiosis G, Tao H. Purine-scaffold Hsp90 inhibitors. iDrugs 2006 (11):778-782.

Hieronymus H, Lamb J, Ross KN, Clement CC, Peng XP, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR. Gene expression signature-based chemical genomic prediction identifies novel class of HSP90 pathway modulators. Cancer Cell 2006, 10(4):321-330.

Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G. Roles of heat shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A 2007 (104), 9511-9516. Highlighted in Alzforum

Du Y, Moulick K, Rodina A, Aguirre J, Felts S, Dingledine R, Fu H, Chiosis G. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. J. Biomolecular Screening 2007 12(7):915-24.

Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, Brodsky LJ, Krystal GW, Chiosis G. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small cell lung cancer. Nat Chem Biol 2007 Aug;3(8):498-507. Recommended Faculty of 1000 Biology

Didelot C, Brunet M, Joly A-L, De Thonel A, Chiosis G, Garrido C. Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins. Curr. Med. Chem. 14, 2007 14(27):2839-47.

Chan CT, Paulmurugan R, Gheysens OS, Kin J, Chiosis G, Gambhir SS. Molecular Imaging of the Efficacy of Heat Shock Protein 90 Inhibitors in Living Subjects. Cancer Res. 2007 68(1):216-26.

Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Disc. Today 2008 13(1-2):38-43.

Chiosis G, Kang Y, Sun W. Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opin. Drug Disc. 2008 3(1):99-114.

C. Didelot, D. Lanneau, M. Brunet, S. Cathelin, J. Cartier, A. Bouchot, N. Decologne, G. Chiosis, L. Dubrez-Daloz, E. Solary, and C. Garrido. HSP90beta by chaperoning c-IAP1 plays an essential role in cell differentiation. Cell Death Differ. 2008 May;15(5):859-66.

Wang L et al. The Chaperone Activity of Heat Shock Protein 90 is Critical for Maintaining the Stability of. Leucine Rich Repeat Kinase 2. J Neurosci. 2008 Mar 26;28(13):3384-91

Kang Y, Taldone T, Clement CC, Fewell SW, Aguirre J, Brodsky JL, Chiosis G. Design of a fluorescence polarization assay platform for the study of human Hsp70. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3749-51.

Goeckeler JL, Petruso AP, Aguirre J, Clement CC, Chiosis G, Brodsky JL. The yeast Hsp110, Sse1p, exhibits high-affinity peptide binding. FEBS Lett. 2008 Jun 6

Ganesh T, Min J, Thepchatri P, Du Y, Li L, Lewis I, Wilson L, Fu H, Chiosis G, Dingledine R, Liotta D, Snyder JP, Sun A. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorg Med Chem. 2008 May 27.

Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008 Aug;8(4):370-4.

Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Res. 2008 Sep 15;68(18):7258-63

Luo W, Rodina A, Chiosis G. Heat shock protein 90: translation from cancer to Alzheimer’s disease treatment? BMC Neurosci. 2008 Dec 3;9 Suppl 2:S7

Taldone T; Chiosis G. Discovery and Development of Heat Shock Protein 90 Inhibitors. Bioorg Med Chem. 2008 Nov 6.

Tao H, Kang Y, Taldone T, Chiosis G. Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines. Bioorg Med Chem Lett. 2009 Jan 15;19(2):415-7.

Caldas-Lopes ME, Cerchietti LC, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina R, White J, Gross SG, Ma Y, Varticovski L, Melnick A & Chiosis G. Heat shock protein 90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73.

Breinig M, Caldas-Lopes EM, Goeppert B, Malz M, Bergmann F, Rieker R, Schirmacher P, Chiosis G, Kern MA. Targeting the heat shock protein Hsp90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009 Jul;50(1):102-12.

Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem. 2009;9(15):1436-46.

Chiosis G, Keeton AB. Assay for isolation of inhibitors of her2-kinase expression. Methods Mol Biol. 2009;486:139-49.

Cerchietti LC, Caldas-Lopes ME, Yang SN, Hatzi K, Robles AI, Walling J, Shaknovich R, Bhalla K, Chiosis G, Melnick AM. A purine scaffold Hsp90 inhibitor destabilizes BCL6 and has specific anti-tumor activity in BCL6 dependent DLBCLs in vitro and in vivo. Nat Med. 2009 Dec;15(12):1369-76 [PMID: PMID: 19966776]

Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, et al. Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab. PLoS ONE 5(1): e8859. doi:10.1371/journal.pone.0008859, 2010

Taldone, T., Zatorska, D., Kang, Y. and Chiosis, G. A facile and efficient synthesis of d6-labelled PU-H71, a purine scaffold Hsp90 inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals. 53(1), 47-49 (2010).

Taldone T, Gillan V, Sun W, Rodina A, Patel P, Maitland K, O'Neill K, Chiosis G, Devaney E. PLoS Negl Trop Dis. 2010 Jun 15;4(6):e714.

Luo W, Sun W, Taldone T, Rodina A, Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener. 2010 Jun 3;5(1):24.

Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J Org Chem. 2010 May 7;75(9):2820-35

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas Lopes-Vazquez E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G and Levine RL. HSP90 as a therapeutic target in JAK2-dependent myeloproliferative neoplasms. J Clin Invest. 2010 Oct 1;120(10):3578-93. Highlighted in Nature/ SciBx issue September 30, 2010

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010 Nov 1. pii: 42869. doi: 10.1172/JCI42869.

Ahn JH, Luo W, Kim J, Rodina A, Clement CC, Aguirre J, Sun W, Kang W, Maharaj R, Moulick K, Zatorska D, Kokoszka M, Brodsky JL, Chiosis G. Design of a flexible cell-based assay for the evaluation of Hsp70 expression modulators. ASSAY and Drug Development Technologies Dec 6 2010.

Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, et al. Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab. PLoS ONE 5(1): e8859. doi:10.1371/journal.pone.0008859, 2010

Taldone, T., Zatorska, D., Kang, Y. and Chiosis, G. A facile and efficient synthesis of d6-labelled PU-H71, a purine scaffold Hsp90 inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals. 53(1), 47-49 (2010).

Taldone T, Gillan V, Sun W, Rodina A, Patel P, Maitland K, O'Neill K, Chiosis G, Devaney E. Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90. PLoS Negl Trop Dis. 2010 Jun 15;4(6):e714.

Luo W, Sun W, Taldone T, Rodina A, Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener. 2010 Jun 3;5(1):24.

Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J Org Chem. 2010 May 7;75(9):2820-35

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas Lopes-Vazquez E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G and Levine RL. HSP90 as a therapeutic target in JAK2-dependent myeloproliferative neoplasms. J Clin Invest. 2010;120(10):3578-93. Highlighted in Nature/ SciBx issue September 30, 2010

Usmani SZ, Chiosis G, Bona RD, et al. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol J 2010 Oct 26;3(1):40.

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010 Nov 1. pii: 42869. doi: 10.1172/JCI42869.

Ahn JH, Luo W, Kim J, Rodina A, Clement CC, Aguirre J, Sun W, Kang W, Maharaj R, Moulick K, Zatorska D, Kokoszka M, Brodsky JL, Chiosis G. Design of a flexible cell-based assay for the evaluation of Hsp70 expression modulators. ASSAY and Drug Development Technologies. 2011 Jun;9(3):236-46.

M Breinig, B Goeppert, M Malz, A Harjung, P Mayer, R Penzel, O Neumann, H Dienemann, G Giaccone, P Schirmacher, G Chiosis, MA Kern, RJ Rieker. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res. 2011 Apr 15;17(8):2237-49.

Patel H, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of HSP90 inhibitors for cancer treatment. Expert Opinion Drug Discovery 2011, Vol. 6, No. 5, 559-587.

Taldone T, Zatorska D, Patel PP, Rodina A, Ahn JH, Moulick K, Chiosis G. Design and Synthesis of Small Molecule Hsp90 Probes. Bioorg Med Chem. 2011;19(8):2603-14.

Taldone T, Gomes-Dagama EM, Zong H, Sen S, Alpaugh ML, Zatorska D, Alonso-Sabadell R, Guzman ML, Chiosis G. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bioorg Med Chem Lett. 2011 Jul 14.

K Moulick, JH Ahn, H Zong, A Rodina, L Cerchietti, EM Gomes DaGama, E Caldas-Lopes, K Beebe, F Perna, K Hatzi, LP Vu, X Zhao, D Zatorska, T Taldone, P Smith-Jones, M Alpaugh, SS. Gross, N Pillarsetty, T Ku, JS Lewis, SM Larson, R Levine, H Erdjument-Bromage, ML Guzman, SD. Nimer, A Melnick, L Neckers, G Chiosis. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chem Biol 2011. 10.1038/NChemBio.670. Featured in Nature News&Views October 20, 2011; Highlighted in Nature issue October 20, 2011; Featured in SciBx October 2011; Featured in ProteoMonitor September 30, 2011

Sun W, Patel P, Chiosis G. An efficient copper catalyzed microwave-assisted S-arylation towards the synthesis of 8-aryl-sulfanyl adenines. SynLett 2011; 20: 3008-3012.

Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2011 doi:10.1016/j.bbamcr.2011.10.008

Taldone T, Zatorska D, Chiosis G. Reaction of 2-naphthylamine with sodium iodate/sodium sulfite: Synthesis of 2-amino-1-iodonaphthalene Synthetic Communications 2012;42(5):635-638.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 2012 Apr 9;209(4):697-711

Brooks JC, Sun W, Chiosis G, Leifer CA. Heat shock protein gp96 regulates Toll-like receptor 9 proteolytic processing and conformational stability. Biochem Biophys Res Commun. 2012 May 18;421(4):780-4.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Jul 22. doi: 10.1038/nature11303. Highlighted in Nature Rev Cancer September 2012.

Chan CT, Reeves RE, Geller R, Yaghoubi SS, Hoehne A, Solow-Cordero DE, Chiosis G, Massoud TF, Paulmurugan R, Gambhir SS. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proc Natl Acad Sci U S A. 2012 Aug 15.

Lisi L, McGuire S, Sharp A, Chiosis G, Navarra P, Feinstein DL, Dello Russo C. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE. J Neuroimmunol. 2013 Feb 15;255(1-2):1-7. doi: 10.1016/j.jneuroim.2012.10.008.

Taldone T, Zatorska D, Patel HJ, Sun W, Patel MR, Chiosis G. Preparation of a diverse purine-scaffold library via one-step palladium catalyzed cross-coupling. Heterocycles, 87, 2013, 91 - 113

Chiosis G, Dickey CA, Johnson JL. A global view of Hsp90 functions. Nat Struct Mol Biol. 2013 Jan;20(1):1-4. Invited report

Taldone T, Rodina A, DaGama& ;Gomes EM, Riolo M, Patel HJ, Alonso-Sabadell R, Zatorska D, Patel MR, Kishinevsky S, Chiosis G. Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes. Beilstein J. Org. Chem. 2013, 9, 544-556. Invited, special issue. Part of Thematic Series; Synthetic probes for the study of biological function

Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-Dagama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET. J Nucl Med. 2013 Apr 11.

Carman A, Kishinevsky S, John Koren III, Lou W, Chiosis G (2013) Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. J Alzheimers Dis Parkinsonism S10:007.doi:10.4172/2161-0460. Invited Special issue Neurodegenerative Disorders

F Hong, B Liu, G Chiosis, DT Gewirth and Z Li. Alpha 7 helix region of Alpha I domain is crucial for integrin binding to ER chaperone gp96: a potential therapeutic target for cancer metastasis. J Biol Chem 288(25):18243-8, 2013

Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L. Posttranslational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget. 2013 Jul 7.

Taldone T, Patel PD, Patel M, Patel HJ, Evans CE, Rodina A, Ochiana S, Shah SK, Uddin M, Gewirth DT, Chiosis G. Experimental and structural testing module to analyze paralog-specificity and affinity in the Hsp90 inhibitors series. J. Med. Chem 2013 DOI: 10.1021/jm400619b, Publication Date (Web): August 21, 2013

Pallav D. Patel, Pengrong Yan, Paul M. Seidler, Hardik J. Patel, Weilin Sun, Chenghua Yang, Nanette S. Que, Tony Taldone, Paola Finotti, Ralph A. Stephani, Daniel T. Gewirth, Gabriela Chiosis. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nature Chemical Biology 2013 doi: 10.01038/nchembio.1335

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013 Aug 13.